Expression of Lysine-specific Demethylase 1 in Human Epithelial Ovarian Cancer

Overview

Journal J Ovarian Res

Publisher Biomed Central

Specialties Gynecology & Obstetrics
Reproductive Medicine

Date 2015 May 10

PMID 25956476

Citations 25

Authors

Cong Chen

Jing Ge

Qibin Lu

Guoqiang Ping

Chunqing Yang

Xuefeng Fang

Affiliations

Soon will be listed here.

Abstract

Background: Lysine-specific demethylase 1(LSD1) is implicated in the tumorigenesis and progression in various cancers. However, the expression of LSD1 in epithelial ovarian cancer and its clinical significance has not been examined in detail.

Methods: Immunohistochemical was used to detect the expression of LSD1 in normal ovarian epithelial tissues, cystadenoma, borderline cystadenoma, and cystadenocarcinoma. Next, the correlations between expression of LSD1 and clinicopathological features was assessed in 96 species of serous cystadenocarcinoma and 36 species of mucinous cystadenocarcinoma.

Results: Immunohistochemical results showed that the expression of LSD1 was gradually increased from benign cystadenoma and borderline cystadenoma to cystadenocarcinoma. The positive ratio of LSD1 expression was 50% in normal ovarian epithelial tissues, 72% in serous cystadenoma, 73% in mucinous cystadenoma, 82% in borderline serous cystadenoma, 83% in borderline mucinous cystadenoma, 94% in serous cystadenocarcinoma and 92% in mucinous cystadenocarcinoma, respectively. LSD1 expression levels were associated with International Federation of Gynecology and Obstetrics stage and lymphatic metastasis in both serous and mucinous cystadenocarcinoma samples. Kaplan-Meier curves suggested that overall survival time of patients with high LSD1 expression was significantly shorter than that of patients with low LSD1 expression. Multivariate Cox proportional hazard regression indicated that higher LSD1 expression was a significant independent predictor of poor survival of EOC patients (P = 0.016).

Conclusions: These results suggest that LSD1 may be involved in carcinogenesis and progression with promising therapeutic potential for epithelial ovarian cancer.

Citing Articles

KDM1A-mediated ZFP64 demethylation activates CENPL to promote epithelial ovarian cancer progression.

Wang J, Fang X, Xing Y, Ding M, Zhu L, Wang M Cytotechnology. 2024; 77(1):10.

PMID: 39628712 PMC: 11609140. DOI: 10.1007/s10616-024-00671-w.

KDM1A/LSD1 inhibition enhances chemotherapy response in ovarian cancer.

Chen Y, Johnson J, Jayamohan S, He Y, Venkata P, Jamwal D Mol Carcinog. 2024; 63(10):2026-2039.

PMID: 38990091 PMC: 11421967. DOI: 10.1002/mc.23792.

Repression of LSD1 potentiates homologous recombination-proficient ovarian cancer to PARP inhibitors through down-regulation of BRCA1/2 and RAD51.

Tao L, Zhou Y, Pan X, Luo Y, Qiu J, Zhou X Nat Commun. 2023; 14(1):7430.

PMID: 37973845 PMC: 10654398. DOI: 10.1038/s41467-023-42850-x.

Domatinostat Targets the FOXM1-Survivin Axis to Reduce the Viability of Ovarian Cancer Cells Alone and in Combination with Chemotherapeutic Agents.

Nakagawa-Saito Y, Mitobe Y, Suzuki S, Togashi K, Sugai A, Kitanaka C Int J Mol Sci. 2023; 24(13).

PMID: 37445993 PMC: 10341571. DOI: 10.3390/ijms241310817.

Design Two Novel Tetrahydroquinoline Derivatives against Anticancer Target LSD1 with 3D-QSAR Model and Molecular Simulation.

Xu Y, Fan B, Gao Y, Chen Y, Han D, Lu J Molecules. 2022; 27(23).

PMID: 36500451 PMC: 9739212. DOI: 10.3390/molecules27238358.

References

Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X . Over-expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One. 2012; 7(4):e35065. PMC: 3320866. DOI: 10.1371/journal.pone.0035065. View

Serce N, Gnatzy A, Steiner S, Lorenzen H, Kirfel J, Buettner R . Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol. 2012; 12:13. PMC: 3511290. DOI: 10.1186/1472-6890-12-13. View

Konovalov S, Garcia-Bassets I . Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian Res. 2013; 6(1):75. PMC: 4176291. DOI: 10.1186/1757-2215-6-75. View

Suikki H, Kujala P, Tammela T, van Weerden W, Vessella R, Visakorpi T . Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate. 2010; 70(8):889-98. DOI: 10.1002/pros.21123. View

Hayami S, Kelly J, Cho H, Yoshimatsu M, Unoki M, Tsunoda T . Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer. 2010; 128(3):574-86. DOI: 10.1002/ijc.25349. View

Ding J, Zhang Z, Xia Y, Liao G, Pan Y, Liu S . LSD1-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer. 2013; 109(4):994-1003. PMC: 3749561. DOI: 10.1038/bjc.2013.364. View

Metzger E, Wissmann M, Yin N, Muller J, Schneider R, Peters A . LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005; 437(7057):436-9. DOI: 10.1038/nature04020. View

Jin L, Hanigan C, Wu Y, Wang W, Park B, Woster P . Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. Biochem J. 2012; 449(2):459-68. PMC: 3525012. DOI: 10.1042/BJ20121360. View

Cho K, Shih I . Ovarian cancer. Annu Rev Pathol. 2008; 4:287-313. PMC: 2679364. DOI: 10.1146/annurev.pathol.4.110807.092246. View

10.

Zhao Z, Yu H, Wang D, Dong P, Chen L, Wu W . Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. World J Gastroenterol. 2012; 18(45):6651-6. PMC: 3516205. DOI: 10.3748/wjg.v18.i45.6651. View

11.

Derr R, van Hoesel A, Benard A, Goossens-Beumer I, Sajet A, Dekker-Ensink N . High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients. BMC Cancer. 2014; 14:604. PMC: 4148956. DOI: 10.1186/1471-2407-14-604. View

12.

Ueda R, Suzuki T, Mino K, Tsumoto H, Nakagawa H, Hasegawa M . Identification of cell-active lysine specific demethylase 1-selective inhibitors. J Am Chem Soc. 2009; 131(48):17536-7. DOI: 10.1021/ja907055q. View

13.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

14.

Ferrari-Amorotti G, Fragliasso V, Esteki R, Prudente Z, Soliera A, Cattelani S . Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion. Cancer Res. 2012; 73(1):235-45. PMC: 3537890. DOI: 10.1158/0008-5472.CAN-12-1739. View

15.

Shi Y, Lan F, Matson C, Mulligan P, Whetstine J, Cole P . Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004; 119(7):941-53. DOI: 10.1016/j.cell.2004.12.012. View

16.

Bradley C, van der Meer R, Roodi N, Yan H, Chandrasekharan M, Sun Z . Carcinogen-induced histone alteration in normal human mammary epithelial cells. Carcinogenesis. 2007; 28(10):2184-92. DOI: 10.1093/carcin/bgm100. View

17.

Hsu H, Liu Y, Tseng K, Yang T, Yeh C, You J . CBB1003, a lysine-specific demethylase 1 inhibitor, suppresses colorectal cancer cells growth through down-regulation of leucine-rich repeat-containing G-protein-coupled receptor 5 expression. J Cancer Res Clin Oncol. 2014; 141(1):11-21. DOI: 10.1007/s00432-014-1782-4. View

18.

Huang J, Sengupta R, Espejo A, Lee M, Dorsey J, Richter M . p53 is regulated by the lysine demethylase LSD1. Nature. 2007; 449(7158):105-8. DOI: 10.1038/nature06092. View

19.

Qin Y, Zhu W, Xu W, Zhang B, Shi S, Ji S . LSD1 sustains pancreatic cancer growth via maintaining HIF1α-dependent glycolytic process. Cancer Lett. 2014; 347(2):225-32. DOI: 10.1016/j.canlet.2014.02.013. View

20.

Willmann D, Lim S, Wetzel S, Metzger E, Jandausch A, Wilk W . Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor. Int J Cancer. 2012; 131(11):2704-9. DOI: 10.1002/ijc.27555. View